Secukinumab Efficacy in TNFi-Naïve & Exposed PsA Patients Compared
Post-hoc analysis of the FUTURE-2 trial was performed to assess if there was a differential treatment responses to secukinumab in TNFi-exposed or naïve patients with active psoriatic arthritis.
